Dublin, April 29, 2019 (GLOBE NEWSWIRE) -- The "Autism - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.


This latest Pharmaceutical and Healthcare disease pipeline guide Autism - Pipeline Review, H1 2019, provides an overview of the Autism (Central Nervous System) pipeline landscape.

Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child's sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.

Report Highlights

This latest pipeline guide Autism - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 8, 6, 1, 20, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System)

Key Topics Covered:

• Autism - Overview
• Autism - Therapeutics Development
• Autism - Therapeutics Assessment
• Autism - Companies Involved in Therapeutics Development
• Autism - Drug Profiles
• Autism - Dormant Projects
• Autism - Discontinued Products
• Autism - Product Development Milestones

List of Tables

• Number of Products under Development for Autism, H1 2019
• Number of Products under Development by Companies, H1 2019
• Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
• Number of Products under Development by Universities/Institutes, H1 2019
• Products under Development by Companies, H1 2019
• Products under Development by Companies, H1 2019 (Contd..1), H1 2019
• Products under Development by Companies, H1 2019 (Contd..2), H1 2019
• Products under Development by Universities/Institutes, H1 2019
• Number of Products by Stage and Target, H1 2019
• Number of Products by Stage and Mechanism of Action, H1 2019
• Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019
• Number of Products by Stage and Route of Administration, H1 2019
• Number of Products by Stage and Molecule Type, H1 2019
• Autism - Pipeline by 4D Pharma PLC, H1 2019
• Autism - Pipeline by AgeneBio Inc, H1 2019
• Autism - Pipeline by AMO Pharma Ltd, H1 2019
• Autism - Pipeline by APeT Holding BV, H1 2019
• Autism - Pipeline by BioHealthonomics Inc, H1 2019
• Autism - Pipeline by Blackthorn Therapeutics Inc, H1 2019
• Autism - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2019
• Autism - Pipeline by Curemark LLC, H1 2019
• Autism - Pipeline by Epigen Biosciences Inc, H1 2019
• Autism - Pipeline by Evgen Pharma Plc, H1 2019
• Autism - Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
• Autism - Pipeline by GlaxoSmithKline Plc, H1 2019
• Autism - Pipeline by GW Pharmaceuticals Plc, H1 2019
• Autism - Pipeline by Immuron Ltd, H1 2019
• Autism - Pipeline by Insys Therapeutics Inc, H1 2019
• Autism - Pipeline by Intra-Cellular Therapies Inc, H1 2019
• Autism - Pipeline by Johnson & Johnson, H1 2019
• Autism - Pipeline by Leading BioSciences Inc, H1 2019
• Autism - Pipeline by Omeros Corp, H1 2019
• Autism - Pipeline by OptiNose US Inc, H1 2019
• Autism - Pipeline by Ovensa Inc, H1 2019
• Autism - Pipeline by Panorama Research Inc, H1 2019
• Autism - Pipeline by RespireRx Pharmaceuticals Inc, H1 2019
• Autism - Pipeline by Reviva Pharmaceuticals Inc, H1 2019

List of Figures

• Number of Products under Development for Autism, H1 2019
• Number of Products under Development by Companies, H1 2019
• Number of Products by Top 10 Targets, H1 2019
• Number of Products by Stage and Top 10 Targets, H1 2019
• Number of Products by Top 10 Mechanism of Actions, H1 2019
• Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
• Number of Products by Top 10 Routes of Administration, H1 2019
• Number of Products by Stage and Top 10 Routes of Administration, H1 2019
• Number of Products by Molecule Types, H1 2019
• Number of Products by Stage and Molecule Types, H1

Companies Mentioned

• 4D Pharma PLC
• AgeneBio Inc
• AMO Pharma Ltd
• APeT Holding BV
• BioHealthonomics Inc
• Blackthorn Therapeutics Inc
• BrainStorm Cell Therapeutics Inc
• Curemark LLC
• Epigen Biosciences Inc
• Evgen Pharma Plc
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline Plc
• GW Pharmaceuticals Plc
• Immuron Ltd
• Insys Therapeutics Inc
• Intra-Cellular Therapies Inc
• Johnson & Johnson
• Leading BioSciences Inc
• Omeros Corp
• OptiNose US Inc
• Ovensa Inc
• Panorama Research Inc
• RespireRx Pharmaceuticals Inc
• Reviva Pharmaceuticals Inc
• Sosei Heptares
• Sumitomo Dainippon Pharma Co Ltd
• Zynerba Pharmaceuticals Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/kso1g1

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs